The PIPE completion removes near-term financing overhang and funds AKTX-101 toward Phase 1. Monitor the June 30 shareholder vote for warrant issuance — approval unlocks additional potential dilution but also signals investor commitment. The stock may re-rate on reduced bankruptcy risk, but clinical execution risk remains high for this micro-cap biotech.
Price Chart
Executive Summary
Akari Therapeutics completed its previously announced PIPE financing, consolidating remaining tranches into a single closing that raised $5.5M in gross proceeds, plus $2.8M from warrant exercises in May, for total Q2 2026 capital of ~$8.3M. The capital infusion extends the cash runway to advance lead ADC candidate AKTX-101 toward a Phase 1 trial by mid-2027, a critical milestone for this pre-revenue biotech. The Q1 EPS miss of -$1.57 vs -$0.69 consensus is overshadowed by the financing event.
Key Financial Metrics
Key Facts
- PIPE completed with $5.5M gross proceeds from sale of 1,470,588 ADSs/prefunded warrants plus Series H/I/J warrants (subject to shareholder approval at June 30 AGM)
- Additional $2.8M from warrant exercises in May 2026, bringing total Q2 capital to ~$8.3M
- Lead candidate AKTX-101 (Trop2-targeting ADC with novel PH1 spliceosome-modulating payload) advancing toward IND-enabling studies with Phase 1 target by mid-2027
- Q1 2026 EPS of -$1.57 missed consensus of -$0.69 by 127.5%, but pre-revenue biotech EPS is not a meaningful metric
- Market cap ~$17M; capital raise represents ~49% of market cap, significantly extending runway
Financial Impact
~$8.3M total capital raised in Q2 2026, representing ~49% of current market cap, providing ~12-18 months of runway for preclinical and early clinical development
Risk Factors
- Shareholder approval required for Series H/I/J warrants — failure would reduce potential future capital
- Dilution from warrant exercises could pressure stock price
- Clinical development risk: AKTX-101 is still preclinical; IND filing and Phase 1 results are 12+ months away
- Micro-cap biotech with high volatility and low liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3318968 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | DEF 14A | $8.72 | awaiting T+60 | — | $8.20 (−5.91%) |
Oct 1, 2026 25d ago | 8-K | $8.72 | awaiting T+60 | — | $8.20 (−5.91%) |
Aug 13, 2026 10w ago | 8-K | $7.54 | awaiting T+60 | — | $8.20 (+8.82%) |
Jul 14, 2026 15w ago | EFFECT | $13.42 $8.63 | ▲ +35.73% | ▲ +39.11% | $8.20 (+38.86%) |
Jul 8, 2026 15w ago | EFFECT | $14.21 $8.84 | ▼ −37.79% | ▼ −40.28% | $8.20 (−42.26%) |
Jul 2, 2026 16w ago | S-3 | $10.41 $9.81 | ▲ +5.76% | ▲ +9.33% | $8.20 (+21.18%) |
Jun 29, 2026 17w ago | Press Release | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.20 (−15.33%) |
Jun 26, 2026 17w ago | 8-K | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.20 (−15.33%) |
May 28, 2026 21w ago | Press Release | $22.05 $7.85 | ▼ −64.40% | ▼ −66.13% | $8.20 (−62.79%) |
May 22, 2026 22w ago | 8-K | $17.81 $7.90 | ▲ +55.64% | ▲ +58.37% | $8.20 (+53.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers